Please ensure Javascript is enabled for purposes of website accessibility

Why Immunovant Stock Is Bouncing Back Today

By Prosper Junior Bakiny - Feb 17, 2021 at 12:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is finally getting a break after a rough past couple of weeks.

What happened?

Shares of clinical-stage biopharmaceutical company Immunovant (IMVT -2.32%) are rising sharply on Wednesday morning and are up by 13.5% as of 11:55 a.m. EST, after jumping by as much as 15.4% earlier today. The drugmaker did not report any news today, at least not yet. What's more, Immunovant is gaining ground despite a Wall Street analyst lowering his price target on the stock. What exactly is going on? 

So what

In early February, Immunovant reported that it had to halt two clinical trials for one of its pipeline candidates, IMVT-1401. The company made this decision after recording cases of elevated total cholesterol and LDL levels in patients treated with the experimental Thyroid Eye Disease treatment. High LDL levels, a form of cholesterol, can lead to severe health consequences such as heart attacks and strokes. Naturally, investors weren't thrilled with this news and responded by selling-off Immunovant's shares. In the past two weeks (or so), the company lost over half its value, with its market cap dropping to $1.8 billion as of this writing (down from more than $4 billion on Feb. 1). 

Letter blocks spelling "avoid."

Image source: Getty Images.

After this steep decline, it seems plausible that institutional investors finally think the risk-reward profile of this biopharmaceutical company is attractive at its current levels and are bidding up its shares as a result. Meanwhile, Credit Suisse analyst Tiago Fauth maintained a neutral rating on the stock and lowered his price target to $26, down from $31. The analyst's new price target still represents a more than 40% upside on Immunovant's stock price. 

Now what

Ultimately, the reasons why Immunovant's stock is gaining ground today don't matter as much as the company's investment thesis. And as things stand, things don't look great for the drugmaker. Immunovant is currently investigating the possible negative adverse reaction observed in patients taking IMVT-1401; no one knows how long this inquiry will last. Moreover, the company has no products on the market and no candidate even close to making it to the market. No matter the price of Immunovant, there are much better healthcare stocks to consider buying.

This article represents the opinion of the writer(s), who may disagree with the "official" recommendation position of a Motley Fool premium advisory service. We're motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immunovant, Inc. Stock Quote
Immunovant, Inc.
IMVT
$3.79 (-2.32%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.